



May 28 2025

Dear Duchenne Community:

We are writing to share the news that we have decided to end development of PGN-EDO51, our investigational therapy to treat people with Duchenne muscular dystrophy amenable to exon 51 skipping. This means that the CONNECT1-EDO51 trial, which has been dosing in Canada, will stop dosing. CONNECT2-EDO51 (proposed for other countries and previously open in the UK) did not dose any participants and will not enroll any participants. This study will now be closed

At PepGen, our goal has always been to change the lives of people with DMD. Unfortunately, we believe that the amount of dystrophin produced by people in the trial is not enough to provide meaningful benefit to people with DMD. We do not believe we can dose at a high enough level to produce an amount of dystrophin that would provide genuine benefit to people with DMD.

We are deeply disappointed by this result, but we feel it is important to make this decision based on current data, and not to further expose people to a therapy that is unlikely to provide an acceptable benefit/risk profile in the long term. Our clinical study sites are working closely with study participants and families to support them through the study wind down.

We understand that this may be very disappointing for you, especially if you were a part of our DMD trials, were considering joining our DMD trials, or are one of the many community members who offered us advice on this program. We know that participation in any clinical trial is a huge commitment on the part of the participants and their families, and we appreciate the time and effort that have been put into helping us find out if this investigational therapy might work. We recognize that the discontinuation of any clinical program may feel like a loss, but please remember each study completed contributes to our understanding of DMD. There are now more therapies in development for DMD than at any point in past history, and many are looking very promising. Please keep in touch with your doctors and local advocacy groups to learn more about other therapies in development.

Most importantly, we want to say THANK YOU for your willingness to be involved in the development of PGN-EDO51 as a potential treatment for DMD. Our commitment to neuromuscular diseases is not diminished by this setback.

With the sincere regards of the entire PepGen team,

Signed by:
Paul Streck
Signer Name: Paul Streck
Signing Reason: I approve this document
Signing Time: 5/27/2025 | 1:59:44 PM PDT
5C9E724ACEF7486A9FFE2191D7F103C6

Signed by:
Jane Larkindale
Signer Name: Jane Larkindale
Signing Reason: I approve this document
Signing Time: 5/27/2025 | 1:58:29 PM PDT
2882DE727BCF43B19FA8CA674E89F668

Paul Streck, MD
Head of Research & Development, PepGen

Jane Larkindale, DPhil
VP Clinical Science and Head of Advocacy